Monitor upcoming catalysts: ReSPECT-LM Phase 2 interim analysis (Q4 2026) and ReSPECT-GBM Phase 2 topline (1H 2027). Track CNSide commercial test volume growth and Medicare rate finalization (CMS pricing expected Nov 2026, rate effective Jan 2027).
Price Chart
Executive Summary
Cerenome filed an 8-K on October 2, 2026, to furnish an updated corporate investor presentation (Exhibit 99.1) dated September 30, 2026. The presentation highlights commercial traction for its CNSide diagnostic platform (24 ordering institutions, 362 commercial YTD tests, 158M covered lives), upcoming Phase 2 data readouts for REYOBIQ (LM interim Q4 2026, GBM topline 1H 2027), and a pipeline of five mid-stage trials. The filing is a routine update of marketing materials with no new financial disclosures or material events.
Key Facts
- CNSide commercial ordering institutions grew from 5 in Q1 to 24 in Q3 2026; 362 commercial TCE specimens YTD.
- 158M contracted covered lives for CNSide; Medicare rate expected effective Jan 1, 2027.
- REYOBIQ ReSPECT-LM Phase 2 interim analysis expected Q4 2026; ReSPECT-GBM Phase 2 topline data expected 1H 2027.
- Five REYOBIQ trials across LM, recurrent GBM, and pediatric brain cancer, each funded by non-dilutive grants.
- CNSide platform expansion planned: Molecular Profile launch Oct 12, 2026; Cellular Biomarkers Nov 2026.
- No financial results, guidance, or material definitive agreements disclosed in this filing.
Financial Impact
No financial figures reported in this filing. Presentation references illustrative list price of ~$15K per CNSide specimen (full menu) but actual reimbursement will vary.
Risk Factors
- CNSide commercial adoption still early (24 institutions, 0 field sales deployed); reimbursement conversion to cash unproven.
- REYOBIQ remains in Phase 2; no approved product or revenue from therapeutics.
- Company flagged going concern risk in forward-looking statements; liquidity and capital raising needs persist.
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-411259 |
| Document: cnsy-ex99_1.htm | 0001193125-26-411259 |
| Document: 0001193125-26-411259-index-headers.html | 0001193125-26-411259 |
| Document: 0001193125-26-411259-index.html | 0001193125-26-411259 |
| Document: 0001193125-26-411259.txt | 0001193125-26-411259 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 25d ago | 8-K | $1.60 | awaiting T+20 | — | $1.60 (+0.00%) |
Sep 30, 2026 27d ago | Press Release | $1.87 | awaiting T+20 | — | $1.60 (−14.44%) |
Sep 22, 2026 5w ago | Press Release | $2.03 $1.68 | ▼ −17.24% | ▼ −16.68% | $1.60 (−21.18%) |
Sep 16, 2026 5w ago | Press Release | $2.04 $1.74 | ▼ −14.71% | ▼ −17.88% | $1.60 (−21.57%) |
Sep 10, 2026 6w ago | 8-K | $2.39 $1.79 | ▲ +25.10% | ▲ +27.23% | $1.60 (+33.05%) |
Aug 14, 2026 10w ago | Press Release | $3.20 $2.12 | ▲ +33.75% | ▲ +31.77% | $1.60 (+50.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers